Aortic Valve StenosisARTiCONCT05235529
Neuropsychological and Neuroimaging Evaluation of the Cognitive Impairment in Aortic Valve Replacement (ARTiCO)
An observational study of Aortic Valve Stenosis and Transcatheter Aortic Valve Replacement, run by Germans Trias i Pujol Hospital at 1 site in Spain.
Trial summary
OBJECTIVE: To evaluate changes in cognitive performance in the early postoperative (1 month) and late (1 year) postoperative period in patients undergoing aortic valve replacement (SVAo) with surgery (SVA_Q) or transcatheter aortic valve implant (TAVI), by neuropsychological study (NRP), structural Brain Magnetic… Read more about this study
- Who is it for?
- Ages 70 to 85 years
- Conditions the study is for
- Aortic Valve Stenosis, Transcatheter Aortic Valve Replacement, Surgical Treatment
- What is being tested?
- Aortic valve replacement and TAVI
- Type of treatment
- Medical device, Surgery or procedure
- How many people
- 72 participants
- Where
- 1 siteSpain
- Study dates
- 4 Jan 2021to Dec 2023
- How long will I take part?
- 3 Years
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 70 to 85 years
- All sexes
- No healthy volunteers
- Older adult
Study population: The population that will be analyzed in this study are those patients with severe aortic stenosis that are candidates on valve replacement treatment. Those who present an intermediate or high surgical risk, over 70 years and who are candidates for both a surgical replacement and a TAVI and who present a normal cognitive state evaluated by a neurologist will be included.
Who may be able to join
- presence of severe / symptomatic aortic stenosis with indication for elective Aortic Valve Replacement
- patients with intermediate or high surgical risk evaluated by EuroScore II 3-10%, susceptible to be treated with both techniques
- age> 70 years
Who cannot join
- contraindication to perform an MRI
- severe renal failure
- severe psychiatric illnesses
- Diagnosed dementia or Mini Mental State Examination (MMSE) <19/35 corrected for age and education
- surgical reintervention
- patients with preoperative comorbidities that condition difficulties for a one-year clinical follow-up
- aortic surgery concomitant to AVS or other than coronary revascularization
Trial locations and contacts
1 site in 1 country.
Spain1 site, 1 recruiting
- Recruiting
Meritxell Gomis Cortina
Badalona, Barcelona, 08917
Meritxell Gomis, MD PhD, 0034934978917, meritxellgomis@gmail.com
About this study
Official title: Neuropsychological and Advanced Neuroimaging Evaluation of the Impact of Cognitive Impairment in Conventional Aortic Valve Replacement Compared to the Transcatheter Implant
OBJECTIVE: To evaluate changes in cognitive performance in the early postoperative (1 month) and late (1 year) postoperative period in patients undergoing aortic valve replacement (SVAo) with surgery (SVA_Q) or transcatheter aortic valve implant (TAVI), by neuropsychological study (NRP), structural Brain Magnetic Resonance (sMRI) and functional MRI (fMRI). The specific objectives are: (1) to compare the early and late clinical-functional consequences with NRP study in both groups; (2) to compare the occurrence of cerebral clinical events during follow-up; (3) to quantify and compare the appearance of silent lesions in the early postoperative period and late of SVAo with sMRI with respect to the baseline MRI in both groups; (4) study with fMRI changes in the activity and functional connectivity and correlate them with the NRP findings in all patients in the early and late phase in comparison with the basal MRI. METHODOLOGY: Prospective longitudinal, unicentric, nonrandomized cohort study of consecutive patients> 70 years, with indication for SVAo and intermediate and high surgical risk. One month before surgery will be performed an sMRI and fMRI and a baseline NRP study. One month after surgery, sMRI, fMRI and NRP study will be performed to assess the appearance of new lesions, as well as changes in cognitive performance with respect to baseline cognitive status. One year later, sMRI, fMRI and NRP study will be performed to assess changes in cognitive status with respect to baseline and early postoperative. Response variables: changes in cognitive performance measured by a Global Cognitive Impairment Index and in cognitive status (normal vs. Mild Cognitive Impairment vs Moderate Impairment), number, size and location of new silent brain lesions, cerebral vascular clinical events, and changes in advanced neuroimaging (image by diffusion tensor (DTI), resting-state fMRI) and its relationship with cognitive changes.
Read the detailed description
Design: Prospective, single-center, longitudinal cohort study with consecutive inclusion of patients older than 70 years of intermediate or high surgical risk who present Aortic Stenoses (AoS) that requires Aortic Valve Replacement (AVS). Two groups will be compared based on the type of treatment received, surgical valve replacement (SVA_Q) or transcatheter aortic valve implantation (TAVI). The choice of treatment will be made according to medical criteria decided by the "heart team" in which clinical cardiologists, hemodynamics and cardiac surgeons participate who follow the recommendations of the European Society Cardiology (ESC / EACTS) 2017 Guidelines. However, only those patients susceptible to treatment with both techniques, will be included. The decision will be agreed with the patient. A complete neuropsychological study and structural and functional MRI will be carried out, one month prior to treatment and one month and year after the procedure. Throughout the study, clinical follow-up will be carried out with evaluation of the appearance of clinical cerebrovascular events.
Study investigators will record the following variables; Once the patient is assigned to treatment, a visit will be scheduled where the surgeon in the case of SVA_Q or the cardiologist in the case of TAVI will assess whether the patient meets the eligibility criteria for the study. If patient fullfill all inclusion and none of exclusion criteria, study investigators will request the Informed Consent.
Baseline clinical variables:
- Age and sex
- Vascular risk factors
- Dyspnea: Functional class (New York Heart Association)
- Chronic obstructive pulmonary disease
- Preoperative Renal Insufficiency
- EuroScore II scale score
- Barthel scale score
- MMSE. The NRP study and neuroimaging will be scheduled for a maximum of one month before the procedure
Intraoperative characteristics:
- Time of extracorporeal circulation, coronary ischemia and orotracheal intubation
- Bleeding from drains
- Blood products transfusion
- Types of prostheses and approach
- Type and anesthetic drugs
During hospital admission:
Defined morbidity at discharge:
- ICU stay> 48 hours, in ward> 10 days
- Respiratory, kidney (RIFLE criteria), infectious, heart rhythm complications (endocavitary pacemaker implant)
- Neurological complications: stroke, transient ischemic attack, disorientation episodes and seizures
- Degree of dependency
- Readmissions (in critical / semi-critical unit)
- Valvular hemodynamics (echocardiographic data)
Mortality at discharge:
- Immediate: <72 hours post-procedure
- Hospital: during hospitalization and / or first 30 days post-procedure Follow-up clinical variables: All complications and mortality at 6 months and 1 year will be collected, as well as valve hemodynamics and functional class in both groups.
Neuropsychological (NPS) variables:
The NRP study scores will be recorded at three times; basal, early and late phase.
Acquisition, analysis of neuropsychological variables:
Neuropsychological tests:
The NPS evaluation will consist of a battery of tests sensitive to vascular pathology (VCI), with an approximate duration of an hour and a half, by a neuropsychologist blind to the patient's treatment group, and will include:
- Attention: Direct Digits subtest (Wechsler Memory Scale III;, WMS III); Symbol Digit Modality Test (SDMT); Symbol Search subtest (Wechsler Adult Intelligence Scale, Wechsler Adult Intelligence Scale (WAIS-III);
- Memory: Rey's 15-word verbal learning test (RAVLT) and Rey's complex figure (RCF) 's Alternative versions of the RAVLT will be used to avoid the retest effect
- Working memory: Digits inverses (WMS III) and Trail Making Test part-B
- Verbal fluency phonetic (P, A, S) and semantics (Animals)
- Visuospatial functions: copy of Rey's complex Figure
- Inhibition: Stroop test
- Visuospatial Speed: Grooved Pegboard and Trail Making Test part-A
- Language: Boston Denomination Test (BNT)
- General cognitive functioning: MMSE and Montreal Cognitive Assessment (MoCA) tests.
The order in the administration of the tests will be constant to avoid variability between subjects due to fatigue. The tests will be administered and scored according to standardized criteria.
To compute the Global Cognitive Impairment Index (IDCG) or Impairment Index (II), first the direct scores obtained in the different neuropsychological tests will be transformed into z scores according to the scales of the normal population and taking into account age and level of schooling. The different tests will be grouped into cognitive domains that have been identified as relevant to detect the cognitive vascular impairment (CVI) to obtain subscripts of speed, attention, memory, language, visuospatial capacity and executive functions. The IDCG will include an average of the different domains evaluated.
In addition, changes in the cognitive status of the patients will also be assessed between the baseline examination, the early and late postoperative period. Specifically, the subjects will be grouped into 3 categories based on performance in the NRP tests: normal, mild cognitive impairment (MCI) and moderate cognitive impairment.
The MCI is defined when the results of the cognitive tests in one or more cognitive domains are 1.5 standard deviations below the mean. The degree of cognitive impairment will be considered moderate when the results of the cognitive tests of one, two or three domains are 2 deviations below the mean or when there is a specific neuropsychological function with 3 standard deviations below the mean.
Image variables
Image acquisition, analysis and variables:
Patients will be assessed by structural and functional MRI at three different times during the study: (1) one month before; (2) one month later, and (3) one year after treatment. These evaluations will be carried out at the Center for Comparative Medicine and Bioimaging of Catalonia (CMCiB) with an MRI (Cannon-3020 Vantage Galen 3 Teslas, with 32-channel cranial bovine) dedicated to biomedical research.
Structural MRI acquisitions will include the acquisition of a high resolution T1-weighted image (MPRAGE), as well as T2-weighted images and fluid attenuated inversion recovery image (FLAIR) with the objective of assessing the presence of lesions of the white matter and lacunar infarcts as well as the appearance of silent lesions. Diffusion-weighted images (DWI) will also be included, which will allow us to assess the integrity of the white matter in the main tracts of the brain. The functional MRI (fMRI) images will include the acquisition of images in a resting-state state and the acquisition of images during the execution of an information processing speed task and an interference inhibition and control task.
In the functional MRI task, two cognitive tasks will be used focused on (a) control and interference (STROOP effect), (b) information processing (Symbol Digit Modality Test, SDMT) that represent the neuroradiological counterpart of neuropsychological tests. These images will allow us to visualize the functional brain areas both in a resting state (changes in the basal functioning of the brain) and during the execution of two tasks that assess cognitive functions (processing speed, working memory, and executive functions) that appear impaired. in vascular-type cognitive impairment. For the correction of the geometric distortions of the magnetic field in the images of MRI both in rest and in task, between 2 and 3 acquisitions of field maps will be carried out. The pre-processing of the images will be carried out with the Finite State Language (FSL) v6 program (FMRIB's Software Library, httpp://www.fmrib.ox.ac.uk/fsl/) and with the Statistical Parametric Mapping program, httpp: / /www.fil.ion.ucl.ac.uk/spm/ (SPM12) . Cortical thickness analysis will be carried out using the Freesurfer program. (httpp://www.surfer.nmr.mgh.harvard.edu/). For the analysis of brain activity at rest, the Analysis of Functional Neuroimages (AFNI) program (httpp://afni.nimh.nih.gov/about_afni) and MELODIC (Multivariate Exploratory Linear Optimized Decomposition into Independent Components) tool included in FSL will be used. For the analysis of fMRI images in task, you wil use (FMRI Expert Analysis tool) v5.98 to explore the functional connectivity between specific brain anatomical regions. The analysis of the diffusion images will be carried out using Tract-Based Spatial Statistics (TBSS), a tool also included in the FSL program, which allows the quantitative comparison of the integrity of the main white matter tracts. For the analysis of structural connectivity, the probabilistic tractography analysis Probabilistic Tracking (Probtrackx2) will be used, included in the FSL program.
- Conditions
- Aortic Valve Stenosis, Transcatheter Aortic Valve Replacement, Surgical Treatment, Cognitive Impairment, Stroke
- Being tested
- Aortic valve replacement, TAVI
- Keywords
- Silent stroke
- Medical subject headings
- Aortic Valve Stenosis, Cognitive Dysfunction, Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Aortic valve replacementProcedure or surgery
Surgery replacement od the aortic valve
TAVIDevice
Transcatheter aortic valve implantation
| Study group | Role | What they receive |
|---|---|---|
| Aortic valve replacement with surgery (SVAo) | This group of patients with severe aortic stenosis will be treated with aortic valve replacement with surgery. Receives: Procedure: Aortic valve replacement | |
| Transcatheter aortic valve implant (TAVI) | This group of patients with severe aortic stenosis will be treated with transcatheter aortic valve implant (TAVI). Receives: Device: TAVI |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from baseline neuropsychological study at early period (one month) after treatment in both groups
Compare the mean score in the cognitive status evaluated with the Neuropsychological study (using the Global Cognitive Impairment Index) in the baseline period and at one month after treatment between both treatment groups (SVA_Q or TAVI). To compute the Global Cognitive Impairment Index (IDCG), first the direct scores obtained in the different neuropsychological tests will be transformed into z scores according to the scales of the normal population and taking into account age and level of schooling. The different tests will be grouped into cognitive domains that have been identified as relevant to detect the cognitive vascular impairment (CVI) to obtain subscripts of speed, attention, memory, language, visuospatial capacity and executive functions. The IDCG will include an average of the different domains evaluated.
Measured: The cognition will be evaluated in two different time frames; at baseline and early period (one month) after the procedures.
Change from baseline neuropsychological study at late period (one year) after treatment in both groups
Compare the mean score in the cognitive status evaluated with the Neuropsychological study (using the Global Cognitive Impairment Index) in the baseline period and at one year after treatment between both treatment groups (SVA_Q or TAVI). To compute the Global Cognitive Impairment Index (IDCG), first the direct scores obtained in the different neuropsychological tests will be transformed into z scores according to the scales of the normal population and taking into account age and level of schooling. The different tests will be grouped into cognitive domains that have been identified as relevant to detect the cognitive vascular impairment (CVI) to obtain subscripts of speed, attention, memory, language, visuospatial capacity and executive functions. The IDCG will include an average of the different domains evaluated.
Measured: The cognition will be evaluated in two different time frames; at baseline and late period (one year) after the procedures.
Change from early period (one month) neuropsychological study at late period (one year) after treatment in both groups
Compare the mean score in the cognitive status evaluated with the Neuropsychological study (using the Global Cognitive Impairment Index) in the early period and at one year after treatment between both treatment groups (SVA_Q or TAVI). To compute the Global Cognitive Impairment Index (IDCG), first the direct scores obtained in the different neuropsychological tests will be transformed into z scores according to the scales of the normal population and taking into account age and level of schooling. The different tests will be grouped into cognitive domains that have been identified as relevant to detect the cognitive vascular impairment (CVI) to obtain subscripts of speed, attention, memory, language, visuospatial capacity and executive functions. The IDCG will include an average of the different domains evaluated.
Measured: The cognition will be evaluated in two different time frames; early period (one month) and late period (one year) after the procedures.
Secondary outcomes (9)
Comparison the incidence of number of new clinical ischemic strokes between both groups after procedures between baseline and one year after treatment (end of follow-up).
Compare the number of new symptomatic ischemic strokes observed in MRI that occur in the postoperative period of aortic valve replacement, between both groups at one year after treatment respect baseline.
Measured: The ischemic strokes will be evaluated in both groups during all the postoperative follow-up, so one year after treatment.
Measure and compare the disability due to new clinical strokes in both groups after procedures and till the end of follow-up.
Describe the clinical strokes that occur in the postoperative period of aortic valve replacement, between both groups till the end of follow-up. To measure the disability due to new clinical strokes the investigators will use mRS. The modified Rankin score (mRS) ranged from 0 to 6. 0 is normal and 6 is dead.
Measured: The ischemic strokes will be evaluated in both groups during all the postoperative follow-up, so one year after treatment.
Comparison the number of silent ischemic lesions (MRI) between both groups after procedures in the early respect baseline period..
Compare the number of silent ischemic lesions that occur in the postoperative period of aortic valve replacement, between both groups in the early respect the baseline period.
Measured: The ischemic silent lesions will be evaluated in both groups in the early (one month) and late period of follow-up (one year), after the procedures.
Comparison the number of silent ischemic lesions (MRI) between both groups after procedures in the late respect baseline period.
Compare the number of silent ischemic lesions that occur in the postoperative period of aortic valve replacement, between both groups in the late respect the baseline period.
Measured: The ischemic silent lesions will be evaluated in both groups in the early (one month) and late period of follow-up (one year), after the procedures.
Comparison the size of silent ischemic lesions (MRI) between both groups after procedures
Compare the total size of all new silent lesions that are observed in the last MRI performed compared to baseline MRI after the aortic valve replacement, between both groups. The size of lesions will be obtained from MRI and calculated in milliliters.
Measured: The ischemic silent lesions will be evaluated in both groups in the early (one month) and late period of follow-up (one year), after the procedures
Incidence of patients changing the cognitive status between baseline to end of follow-up in both groups and the correlation between this change and the number of new silent lesions in one year MRI.
Rate of patients that change the cognitive status (normal; mild cognitive impairment; moderate cognitive impairment) measured with the MMSE between baseline and the end of follow-up in both groups and related with the number of new silent lesions observed in MRI between baseline to one year MRI. The cognitive status is evaluated with MMSE. Normal >25; mild cognitive impairment 20-24 and moderate cognitive impairment <15. The new silent lesions will be a number and a correlation will be done.
Measured: Cognitive status (MMSE) and silent lesions will be obtained at baseline, one month and one year.
Incidence of patients changing the cognitive status between baseline to end of follow-up in both groups and the correlation between this change with the structural data obtained with MRI
Rate of patients that change the cognitive status (normal; mild cognitive impairment; moderate cognitive impairment) measured with the MMSE between baseline and the end of follow-up in both groups and related with the neuroanatomical data of the MRI (DTI, T1-weighted image, as well as T2-weighted images and fluid attenuated inversion recovery image (FLAIR) with the objective of assessing the presence of lesions of the white matter and lacunar infarcts as well as the appearance of silent lesions) between baseline to one year MRI. The cognitive status is evaluated with MMSE. Normal >25; mild cognitive impairment 20-24 and moderate cognitive impairment <15. The presence in number of lacunar infarcts and the volume in cc of lesions of the white matter will be calculated and a correlation will be done.
Measured: The data obtained with structural MRI will be compared with cognitive status one year after the procedures.
Rate of patients changing the cognitive status between baseline to end of follow-up in both groups and the relationship between this change with the functional data obtained with MRI
Rate of patients that change the cognitive status (normal; mild cognitive impairment; moderate cognitive impairment) measured with the MMSE between baseline and the end of follow-up in both groups and related with the functional data of the MRI (resting state) between baseline to one year MRI. The cognitive status is evaluated with MMSE. Normal >25; mild cognitive impairment 20-24 and moderate cognitive impairment <15.
Measured: The data obtained with functional MRI will be compared with cognitive status one year after the procedures.
Assess changes in functional networks in those patients that developed cognitive impairment during the study (one year)
Assess whether there are or not changes in the following functional networks; Default Mode Network (DMN), Salience Network (SN), Central Executive Network (CEN) in subjects who develop cognitive impairment in both groups. Cognitive impairment will be measured with MMSE. It will be considered cognitive impairment if MMSE<25.
Measured: Evaluation of functional networks at baseline and at an average of one year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Feb 2022
- Study start4 Jan 2021
- Primary completionMar 2022 (estimated)
- Study completionDec 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Aortic Valve StenosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 72 participants (estimated)
- Target duration
- 3 Years
Sponsor and investigators
- Lead sponsor
- Germans Trias i Pujol Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Instituto de Salud Carlos III
- Responsible party
- Sponsor
- Investigators
- Meritxell Gomis, MD, PhD, Principal investigator, Germans Trias i Pujol Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05235529
- Sponsor's protocol ID
- HUGTiP_ISC III_ PI19/01397
- Acronym
- ARTiCO
- Status last verified
- Nov 2021
- First submitted
- 15 Jun 2021
- Last updated
- 11 Feb 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Gomis M, Fernandez C, Dacosta-Aguayo R, Carrillo X, Martinez S, Guijosa CM, Berastegui E, Valentin AG, Puig J, Bernal E, Ramos A, Caceres C. Aortic valve Replacement compared to Transcatheter Implant and its relationship with COgnitive Impairment (ARTICO) evaluated with neuropsychological and advanced neuroimaging: a longitudinal cohort study. BMC Neurol. 2023 Aug 23;23(1):310. doi: 10.1186/s12883-023-03362-9.
PubMed 37612651
Study at a glance
From the registry record, last updated by the sponsor on 11 Feb 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Neuropsychological and Advanced Neuroimaging Evaluation of the Impact of Cognitive Impairment in Conventional Aortic Valve Replacement Compared to the Transcatheter Implant
- ClinicalTrials.gov ID
- NCT05235529
- Acronym / sponsor ID
- ARTiCO / HUGTiP_ISC III_ PI19/01397
- Conditions
- Aortic Valve Stenosis, Transcatheter Aortic Valve Replacement, Surgical Treatment, Cognitive Impairment, Stroke
- Keywords
- Silent stroke
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 72 participants (estimated)
- Lead sponsor
- Germans Trias i Pujol HospitalUniversity, hospital or other
- Collaborators
- Instituto de Salud Carlos III
- Study start
- 4 Jan 2021 (actual)
- Primary completion
- Mar 2022 (estimated)
- Study completion
- Dec 2023 (estimated)
- First posted
- 11 Feb 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
OBJECTIVE: To evaluate changes in cognitive performance in the early postoperative (1 month) and late (1 year) postoperative period in patients undergoing aortic valve replacement (SVAo) with surgery (SVA_Q) or transcatheter aortic valve implant (TAVI), by neuropsychological study (NRP), structural Brain Magnetic Resonance (sMRI) and functional MRI (fMRI). The specific objectives are: (1) to compare the early and late clinical-functional consequences with NRP study in both groups; (2) to compare the occurrence of cerebral clinical events during follow-up; (3) to quantify and compare the appearance of silent lesions in the early postoperative period and late of SVAo with sMRI with respect to the baseline MRI in both groups; (4) study with fMRI changes in the activity and functional connectivity and correlate them with the NRP findings in all patients in the early and late phase in comparison with the basal MRI. METHODOLOGY: Prospective longitudinal, unicentric, nonrandomized cohort study of consecutive patients> 70 years, with indication for SVAo and intermediate and high surgical risk. One month before surgery will be performed an sMRI and fMRI and a baseline NRP study. One month after surgery, sMRI, fMRI and NRP study will be performed to assess the appearance of new lesions, as well as changes in cognitive performance with respect to baseline cognitive status. One year later, sMRI, fMRI and NRP study will be performed to assess changes in cognitive status with respect to baseline and early postoperative. Response variables: changes in cognitive performance measured by a Global Cognitive Impairment Index and in cognitive status (normal vs. Mild Cognitive Impairment vs Moderate Impairment), number, size and location of new silent brain lesions, cerebral vascular clinical events, and changes in advanced neuroimaging (image by diffusion tensor (DTI), resting-state fMRI) and its relationship with cognitive changes.
Detailed description
Design: Prospective, single-center, longitudinal cohort study with consecutive inclusion of patients older than 70 years of intermediate or high surgical risk who present Aortic Stenoses (AoS) that requires Aortic Valve Replacement (AVS). Two groups will be compared based on the type of treatment received, surgical valve replacement (SVA_Q) or transcatheter aortic valve implantation (TAVI). The choice of treatment will be made according to medical criteria decided by the "heart team" in which clinical cardiologists, hemodynamics and cardiac surgeons participate who follow the recommendations of the European Society Cardiology (ESC / EACTS) 2017 Guidelines. However, only those patients susceptible to treatment with both techniques, will be included. The decision will be agreed with the patient. A complete neuropsychological study and structural and functional MRI will be carried out, one month prior to treatment and one month and year after the procedure. Throughout the study, clinical follow-up will be carried out with evaluation of the appearance of clinical cerebrovascular events.
Study investigators will record the following variables; Once the patient is assigned to treatment, a visit will be scheduled where the surgeon in the case of SVA_Q or the cardiologist in the case of TAVI will assess whether the patient meets the eligibility criteria for the study. If patient fullfill all inclusion and none of exclusion criteria, study investigators will request the Informed Consent.
Baseline clinical variables:
- Age and sex
- Vascular risk factors
- Dyspnea: Functional class (New York Heart Association)
- Chronic obstructive pulmonary disease
- Preoperative Renal Insufficiency
- EuroScore II scale score
- Barthel scale score
- MMSE. The NRP study and neuroimaging will be scheduled for a maximum of one month before the procedure
Intraoperative characteristics:
- Time of extracorporeal circulation, coronary ischemia and orotracheal intubation
- Bleeding from drains
- Blood products transfusion
- Types of prostheses and approach
- Type and anesthetic drugs
During hospital admission:
Defined morbidity at discharge:
- ICU stay> 48 hours, in ward> 10 days
- Respiratory, kidney (RIFLE criteria), infectious, heart rhythm complications (endocavitary pacemaker implant)
- Neurological complications: stroke, transient ischemic attack, disorientation episodes and seizures
- Degree of dependency
- Readmissions (in critical / semi-critical unit)
- Valvular hemodynamics (echocardiographic data)
Mortality at discharge:
- Immediate: <72 hours post-procedure
- Hospital: during hospitalization and / or first 30 days post-procedure Follow-up clinical variables: All complications and mortality at 6 months and 1 year will be collected, as well as valve hemodynamics and functional class in both groups.
Neuropsychological (NPS) variables:
The NRP study scores will be recorded at three times; basal, early and late phase.
Acquisition, analysis of neuropsychological variables:
Neuropsychological tests:
The NPS evaluation will consist of a battery of tests sensitive to vascular pathology (VCI), with an approximate duration of an hour and a half, by a neuropsychologist blind to the patient's treatment group, and will include:
- Attention: Direct Digits subtest (Wechsler Memory Scale III;, WMS III); Symbol Digit Modality Test (SDMT); Symbol Search subtest (Wechsler Adult Intelligence Scale, Wechsler Adult Intelligence Scale (WAIS-III);
- Memory: Rey's 15-word verbal learning test (RAVLT) and Rey's complex figure (RCF) 's Alternative versions of the RAVLT will be used to avoid the retest effect
- Working memory: Digits inverses (WMS III) and Trail Making Test part-B
- Verbal fluency phonetic (P, A, S) and semantics (Animals)
- Visuospatial functions: copy of Rey's complex Figure
- Inhibition: Stroop test
- Visuospatial Speed: Grooved Pegboard and Trail Making Test part-A
- Language: Boston Denomination Test (BNT)
- General cognitive functioning: MMSE and Montreal Cognitive Assessment (MoCA) tests.
The order in the administration of the tests will be constant to avoid variability between subjects due to fatigue. The tests will be administered and scored according to standardized criteria.
To compute the Global Cognitive Impairment Index (IDCG) or Impairment Index (II), first the direct scores obtained in the different neuropsychological tests will be transformed into z scores according to the scales of the normal population and taking into account age and level of schooling. The different tests will be grouped into cognitive domains that have been identified as relevant to detect the cognitive vascular impairment (CVI) to obtain subscripts of speed, attention, memory, language, visuospatial capacity and executive functions. The IDCG will include an average of the different domains evaluated.
In addition, changes in the cognitive status of the patients will also be assessed between the baseline examination, the early and late postoperative period. Specifically, the subjects will be grouped into 3 categories based on performance in the NRP tests: normal, mild cognitive impairment (MCI) and moderate cognitive impairment.
The MCI is defined when the results of the cognitive tests in one or more cognitive domains are 1.5 standard deviations below the mean. The degree of cognitive impairment will be considered moderate when the results of the cognitive tests of one, two or three domains are 2 deviations below the mean or when there is a specific neuropsychological function with 3 standard deviations below the mean.
Image variables
Image acquisition, analysis and variables:
Patients will be assessed by structural and functional MRI at three different times during the study: (1) one month before; (2) one month later, and (3) one year after treatment. These evaluations will be carried out at the Center for Comparative Medicine and Bioimaging of Catalonia (CMCiB) with an MRI (Cannon-3020 Vantage Galen 3 Teslas, with 32-channel cranial bovine) dedicated to biomedical research.
Structural MRI acquisitions will include the acquisition of a high resolution T1-weighted image (MPRAGE), as well as T2-weighted images and fluid attenuated inversion recovery image (FLAIR) with the objective of assessing the presence of lesions of the white matter and lacunar infarcts as well as the appearance of silent lesions. Diffusion-weighted images (DWI) will also be included, which will allow us to assess the integrity of the white matter in the main tracts of the brain. The functional MRI (fMRI) images will include the acquisition of images in a resting-state state and the acquisition of images during the execution of an information processing speed task and an interference inhibition and control task.
In the functional MRI task, two cognitive tasks will be used focused on (a) control and interference (STROOP effect), (b) information processing (Symbol Digit Modality Test, SDMT) that represent the neuroradiological counterpart of neuropsychological tests. These images will allow us to visualize the functional brain areas both in a resting state (changes in the basal functioning of the brain) and during the execution of two tasks that assess cognitive functions (processing speed, working memory, and executive functions) that appear impaired. in vascular-type cognitive impairment. For the correction of the geometric distortions of the magnetic field in the images of MRI both in rest and in task, between 2 and 3 acquisitions of field maps will be carried out. The pre-processing of the images will be carried out with the Finite State Language (FSL) v6 program (FMRIB's Software Library, httpp://www.fmrib.ox.ac.uk/fsl/) and with the Statistical Parametric Mapping program, httpp: / /www.fil.ion.ucl.ac.uk/spm/ (SPM12) . Cortical thickness analysis will be carried out using the Freesurfer program. (httpp://www.surfer.nmr.mgh.harvard.edu/). For the analysis of brain activity at rest, the Analysis of Functional Neuroimages (AFNI) program (httpp://afni.nimh.nih.gov/about_afni) and MELODIC (Multivariate Exploratory Linear Optimized Decomposition into Independent Components) tool included in FSL will be used. For the analysis of fMRI images in task, you wil use (FMRI Expert Analysis tool) v5.98 to explore the functional connectivity between specific brain anatomical regions. The analysis of the diffusion images will be carried out using Tract-Based Spatial Statistics (TBSS), a tool also included in the FSL program, which allows the quantitative comparison of the integrity of the main white matter tracts. For the analysis of structural connectivity, the probabilistic tractography analysis Probabilistic Tracking (Probtrackx2) will be used, included in the FSL program.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 3 Years
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Aortic valve replacement with surgery (SVAo) | – | Procedure: Aortic valve replacementThis group of patients with severe aortic stenosis will be treated with aortic valve replacement with surgery. |
| Transcatheter aortic valve implant (TAVI) | – | Device: TAVIThis group of patients with severe aortic stenosis will be treated with transcatheter aortic valve implant (TAVI). |
Who may qualify
- Ages
- 70 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
- Study population
- The population that will be analyzed in this study are those patients with severe aortic stenosis that are candidates on valve replacement treatment. Those who present an intermediate or high surgical risk, over 70 years and who are candidates for both a surgical replacement and a TAVI and who present a normal cognitive state evaluated by a neurologist will be included.
Key inclusion criteria (3 listed)
- presence of severe / symptomatic aortic stenosis with indication for elective Aortic Valve Replacement
- patients with intermediate or high surgical risk evaluated by EuroScore II 3-10%, susceptible to be treated with both techniques
- age> 70 years
Key exclusion criteria (7 listed)
- contraindication to perform an MRI
- severe renal failure
- severe psychiatric illnesses
- Diagnosed dementia or Mini Mental State Examination (MMSE) <19/35 corrected for age and education
- surgical reintervention
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Aortic valve replacementSurgery replacement od the aortic valve | Procedure or surgery | Aortic valve replacement with surgery (SVAo) |
| TAVITranscatheter aortic valve implantation | Device | Transcatheter aortic valve implant (TAVI) |
Primary outcome
Change from baseline neuropsychological study at early period (one month) after treatment in both groups
Time frame: The cognition will be evaluated in two different time frames; at baseline and early period (one month) after the procedures.
Compare the mean score in the cognitive status evaluated with the Neuropsychological study (using the Global Cognitive Impairment Index) in the baseline period and at one month after treatment between both treatment groups (SVA_Q or TAVI). To compute the Global Cognitive Impairment Index (IDCG), first the direct scores obtained in the different neuropsychological tests will be transformed into z scores according to the scales of the normal population and taking into account age and level of schooling. The different tests will be grouped into cognitive domains that have been identified as relevant to detect the cognitive vascular impairment (CVI) to obtain subscripts of speed, attention, memory, language, visuospatial capacity and executive functions. The IDCG will include an average of the different domains evaluated.
Change from baseline neuropsychological study at late period (one year) after treatment in both groups
Time frame: The cognition will be evaluated in two different time frames; at baseline and late period (one year) after the procedures.
Compare the mean score in the cognitive status evaluated with the Neuropsychological study (using the Global Cognitive Impairment Index) in the baseline period and at one year after treatment between both treatment groups (SVA_Q or TAVI). To compute the Global Cognitive Impairment Index (IDCG), first the direct scores obtained in the different neuropsychological tests will be transformed into z scores according to the scales of the normal population and taking into account age and level of schooling. The different tests will be grouped into cognitive domains that have been identified as relevant to detect the cognitive vascular impairment (CVI) to obtain subscripts of speed, attention, memory, language, visuospatial capacity and executive functions. The IDCG will include an average of the different domains evaluated.
Change from early period (one month) neuropsychological study at late period (one year) after treatment in both groups
Time frame: The cognition will be evaluated in two different time frames; early period (one month) and late period (one year) after the procedures.
Compare the mean score in the cognitive status evaluated with the Neuropsychological study (using the Global Cognitive Impairment Index) in the early period and at one year after treatment between both treatment groups (SVA_Q or TAVI). To compute the Global Cognitive Impairment Index (IDCG), first the direct scores obtained in the different neuropsychological tests will be transformed into z scores according to the scales of the normal population and taking into account age and level of schooling. The different tests will be grouped into cognitive domains that have been identified as relevant to detect the cognitive vascular impairment (CVI) to obtain subscripts of speed, attention, memory, language, visuospatial capacity and executive functions. The IDCG will include an average of the different domains evaluated.
9 secondary outcomes
Comparison the incidence of number of new clinical ischemic strokes between both groups after procedures between baseline and one year after treatment (end of follow-up).
Time frame: The ischemic strokes will be evaluated in both groups during all the postoperative follow-up, so one year after treatment.
Measure and compare the disability due to new clinical strokes in both groups after procedures and till the end of follow-up.
Time frame: The ischemic strokes will be evaluated in both groups during all the postoperative follow-up, so one year after treatment.
Comparison the number of silent ischemic lesions (MRI) between both groups after procedures in the early respect baseline period..
Time frame: The ischemic silent lesions will be evaluated in both groups in the early (one month) and late period of follow-up (one year), after the procedures.
Comparison the number of silent ischemic lesions (MRI) between both groups after procedures in the late respect baseline period.
Time frame: The ischemic silent lesions will be evaluated in both groups in the early (one month) and late period of follow-up (one year), after the procedures.
Comparison the size of silent ischemic lesions (MRI) between both groups after procedures
Time frame: The ischemic silent lesions will be evaluated in both groups in the early (one month) and late period of follow-up (one year), after the procedures
Incidence of patients changing the cognitive status between baseline to end of follow-up in both groups and the correlation between this change and the number of new silent lesions in one year MRI.
Time frame: Cognitive status (MMSE) and silent lesions will be obtained at baseline, one month and one year.
Incidence of patients changing the cognitive status between baseline to end of follow-up in both groups and the correlation between this change with the structural data obtained with MRI
Time frame: The data obtained with structural MRI will be compared with cognitive status one year after the procedures.
Rate of patients changing the cognitive status between baseline to end of follow-up in both groups and the relationship between this change with the functional data obtained with MRI
Time frame: The data obtained with functional MRI will be compared with cognitive status one year after the procedures.
Assess changes in functional networks in those patients that developed cognitive impairment during the study (one year)
Time frame: Evaluation of functional networks at baseline and at an average of one year
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Feb 2022.
- Derived from this study: PubMed 37612651Gomis M, Fernandez C, Dacosta-Aguayo R, Carrillo X, Martinez S, Guijosa CM, Berastegui E, Valentin AG, Puig J, Bernal E, Ramos A, Caceres C. Aortic valve Replacement compared to Transcatheter Implant and its relationship with COgnitive Impairment (ARTICO) evaluated with neuropsychological and advanced neuroimaging: a longitudinal cohort study. BMC Neurol. 2023 Aug 23;23(1):310. doi: 10.1186/s12883-023-03362-9.
Related trials for Aortic Valve Stenosis
Recruiting
Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR
Aortic Stenosis Treated With TAVI, Aortic Diseases
Not yet recruiting
Human Experimental Models of Pain (HEMP)
Acute Pain
Active, not recruitingObservational study
Intravascular Lithotripsy in High Risk Calcified Iliac Anatomy for Transfemoral TAVR
Iliac Disease, Aortic Valve Stenosis
Not yet recruiting
NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label Devices
Hypertrophic Cardiomyopathy, Left Ventricular Outflow Obstruction
Recruiting
Exercise and Diet Supplements for Older Patients Undergoing TAVI: the IRON-TAVI Trial
Aortic Stenosis Disease, Aortic Stenosis Symptomatic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Meritxell Gomis, MD, PhD principal investigator
Germans Trias i Pujol Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Aortic Valve Stenosis and Transcatheter Aortic Valve Replacement, run by Germans Trias i Pujol Hospital at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 11 Feb 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Meritxell Gomis, MD, PhD (606 22 99 97, meritxellgomis@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from baseline neuropsychological study at early period (one month) after treatment in both groups (time frame: The cognition will be evaluated in two different time frames; at baseline and early period (one month) after the procedures.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05235529, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Feb 2022.